Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2013
At a glance
- Drugs Vorinostat (Primary) ; Bortezomib
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2012 Actual end date changed from Jul 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date changed from Nov 2010 to Jul 2010 as reported by ClinicalTrials.gov.